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The expression and induction of metallothionein has been associated with protection against oxidative stress and apoptosis.
This study examines the effect of tumour suppressor protein p53 on metallothionein expression following CdCl2 treatment in
eight human epithelial breast cancer cell lines differing in p53 and oestrogen-receptor status. Cells were treated with 10 mM
CdCl2 for 24 h and metallothionein protein levels were measured by cadmium binding assay. MCF7 cells which are p53-
positive (p53+) and oestrogen-receptor-positive showed a large induction in metallothionein synthesis by 10.79+1.36-fold.
Other breast cancer cell lines which are p53-negative (p537) and oestrogen-receptor-negative or weakly oestrogen-
receptor-positive showed a small induction ranging from 1.40+0.10 to 3.65+0.30-fold. RT–PCR analysis showed an
induction of metallothionein mRNA in MCF7 cells by about 1.61+0.08-fold, while in HCC1806 cells (p537, oestrogen-
receptor-negative) by 1.11+0.13-fold, and in MDA-MB-231 (p537, oestrogen-receptor-negative) by 1.25+0.06-fold.
Metallothionein localisation was determined by immunohistochemical staining. Prior to metal treatment, metallothionein was
localised mainly in the cytoplasm of MCF7 and MDA-MB-231 cells. After treatment with 10 mM CdCl2 for 24 h, MCF7 cells
showed intense nuclear and cytoplasmic staining for metallothionein, while MDA-MB-231 cells showed staining in the
cytoplasm with weak nuclear staining. Apoptosis induced by 10–40 mM CdCl2 at time points between 4 and 48 h was
examined with TUNEL assay. In MCF7 cells, apoptosis increased with higher concentrations of CdCl2, it peaked at 6–8 h and
appeared again at 48 h for all concentrations of CdCl2 tested. In MDA-MB-231 cells, apoptosis remained at low levels for
10–40 mM CdCl2 at all time points. Studies on cadmium uptake showed similar uptake and accumulation of cadmium at 8
and 24 h in all the cell lines. The data demonstrate that treatment of epithelial breast cancer cells with 10 mM CdCl2 for 24 h
caused a greater induction of metallothionein protein and mRNA expression in p53+ and oestrogen-receptor-positive cells as
compared to p537 and oestrogen-receptor-negative or weakly oestrogen-receptor-positive cells. This effect may be
associated with the occurrence of apoptosis and suggests a role for p53 and oestrogen-receptor on the expression and
induction of metallothionein in epithelial cells.
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The expression and induction of metallothionein (MT) has gener-
ally been associated with protection against oxidative stress and
apoptosis. It has been reported that MT-null mice and cells
derived from them were more sensitive to the toxic effects of
heavy metals such as cadmium (Klaassen et al, 1999), toxic
agents such as hydrogen peroxide and tert-butyl hydroperoxide
(Chubatsu and Meneghini, 1993; Schwarz et al, 1994), and radia-
tion exposure (Cai et al, 1999) as compared to MT-wildtype and
MT I-overexpressing mice. Cells pre-induced to express MT were
also more resistant against the toxic effects of cadmium (Goering
and Klaassen, 1984; Klaassen et al, 1999) and radiation exposure
(Cai et al, 1999) as compared to control cells. In human T cell
and breast carcinoma cell lines, down-regulation of MT with
antisense MT oligomers not only inhibited growth of the cells,
but also activated apoptosis (Abedel-Mageed and Agrawal, 1997;
Tsangaris and Tzortzatou-Stathopoulou, 1998). In studies using
tumour cell lines, it was found that tumour cells with a high
expression of MT were more resistant against the toxic effects
of anticancer agents such as cisplatin as well as radiation expo-
sure (Kondo et al, 1995; Lazo et al, 1998). In addition, in
both human primary hepatocellular carcinoma and metastatic
carcinoma, the MT levels were low and had higher number of
apoptotic cells as compared to normal liver (Cai et al, 1998;
Deng et al, 1998).
The potential role of MT on modulation of apoptosis is unclear.
Antioxidant properties of MT may contribute to its protective
effects (Greenstock et al, 1987; Cai et al, 1996). In fact, the synth-
esis of MT was shown to be induced several-fold during oxidative
stress (Sato and Bremner, 1993) to protect the cells against cyto-
toxicity (Aschner et al, 1998) and DNA damage (Cai et al,
1995). In particular, MT synthesis is induced following treatment
with cadmium, an environmental pollutant that is able to cause
oxidative stress, DNA damage and apoptosis (El Azzouzi et al,
1994; Yang et al, 1997). The protective role of MT may also depend
on the nuclear/cytoplasmic localisation of MT in the cell. In gener-
al, cytoplasmic MT protects against cytotoxicity whereas nuclear
MT protects against genotoxicity (Schwarz et al, 1994; Woo and
Lazo, 1997; Cherian and Apostolova, 2000).
The tumour suppressor protein p53 is one of the most
frequently activated proteins in apoptosis. p53 is able to
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www.bjcancer.comrespond to different cellular stresses such as DNA damage,
hypoxia, oxidative stress, and oncogene activation. Upon activa-
tion, p53 initiates a number of cellular activities that can
ultimately culminate in G1 or G2 cell cycle arrest and DNA
repair, apoptosis, or other cellular changes (Schwartz and
Rotter, 1998). As a critical cellular mediator of the response
to genotoxic damage, P53 has a direct role in maintaining
the integrity of the genome. Loss of p53 activity has been asso-
ciated with tumour progression and unfavourable prognosis of
the tumour (Symonds et al, 1994). Recently, it was found that
an association exists between MT expression and p53 expression
in small cell carcinoma of the lung (Joseph et al, 2001). Since
both MT and p53 are involved in responding to oxidative stress
and apoptosis, the present study was undertaken to investigate
the effect of p53 on MT expression and induction in human
epithelial breast cancer cells.
MT expression in breast cancer has been associated with a lower
number of apoptotic cells (Abdel-Mageed and Agrawal, 1997) and
a poor prognosis of the cancer (Haerslev et al, 1995; Oyama et al,
1996). Recently, certain studies have demonstrated that oestrogen
receptor-positive (ER+) breast cancer cells showed lower expres-
sion of MT as compared to oestrogen receptor-negative (ER7)
cells (Friedline et al, 1998). Possibly, p53 may be another factor
in determining MT expression. Since p53 is mutated in more than
70% of human breast cancers (Callahan and Campbell, 1989), it is
possible to examine the effects of p53-positive (p53+) as well as
p53-negative (p537) breast cancer cell lines. These cell lines also
show differential expression of oestrogen receptor. In this study,
MT expression and induction following cadmium exposure were
investigated in eight epithelial breast cancer cell lines differing in
p53 and ER expression.
MATERIALS AND METHODS
Cell culture
Human epithelial breast cancer cell lines MCF7 and HCC1806 were
obtained from Dr Rodenheiser; HCC1419 and HCC1569 from
ATCC; MDA-MB-231, MDA-MB-468 and HS578t from Drs Laird
and Lala; and MDA-MB-435 from Drs Ferguson and Koropatnick.
MCF7 cells were grown in Dulbecco’s Modiﬁed Essential Medium
(DMEM) supplemented with 10% foetal bovine serum (FBS).
HCC1806, HCC1419, HCC1569, MDA-MB-231 and MDA-MB-
468 cells were grown in RPMI1640 medium supplemented with
10% FBS. HS578t cells were grown in RPMI1640 medium supple-
mented with 10% FBS and 10 mgm l
71 of insulin. MDA-MB-435
cells were grown in Minimum Essential Medium Alpha containing
ribonucleosides and deoxyribonucleosides and supplemented with
10% FBS. The epithelial breast cancer cell lines differ in p53 and
ER expression (Table 1).
Cell viability assay
Cell viability following CdCl2 treatment was measured using
Intergen’s Procheck Cell Viability Assay (Intergen Co., Purchase,
NY, U.S.A.) based on the conversion of XTT (sodium3,3'-{1-
[(phenylamino)carbonyl]-3,4-tetrazolium}bis(4-methoxy-6-nitro)-
benzene sulphonic acid) from an oxidized tetrazole to a reduced
formazan (Scudiero et al, 1988). Cells were seeded into 96-well
plates with 10
4 cells well
71 and allowed to attach for 24 h.
Cells were treated with 10–100 mM of CdCl2 for 12 h and then
washed twice with PBS to stop the treatment. To the wells,
100 ml of media and 20 ml of the assay reagent were added
and cells were incubated under growth conditions for 4 h. Opti-
cal densities were read at 475 nm in a microplate
spectrophotometer and cell viability was expressed as a per cent
of control.
Estimation of MT
Cells grown in 75-cm
2 T ﬂasks were treated with 10 mM CdCl2 for
24 h and then washed twice with PBS. Cells were collected by
trypsinisation followed by centrifugation at 2000 r.p.m. for
2 min. Quantiﬁcation of MT was performed by a
109cadmium-
haeme saturation assay as previously described (Eaton and Cher-
ian, 1991). Brieﬂy, the cell pellet was resuspended in 630 mlo f
deionised water and frozen and thawed to lyse the cells. To a
300 ml aliquot, 1 ml of a 30 mM Tris-HCl buffer (pH 8.0) and
1 ml of a 5 p.p.m.
109Cd solution with known speciﬁc activity
were added to saturate the metal-binding sites of MT. Rat haemo-
lysate was added to remove excess Cd, followed by heat treatment
in a water bath to precipitate Cd-hemoglobin and other proteins,
with the exception of MT which is heat stable. The denatured
proteins were then removed by centrifugation at 10000 r.p.m.
for 2 min. The steps of haemolysate addition, heat denaturation
and centrifugation were repeated three times. The Cd concentra-
tions in the ﬁnal supernatant were calculated from the
radioactivity of the
109Cd measured by a g counter (1272 Clini-
gamma, LKB Wallac; Turku, Finland), with a counting efﬁciency
of 75%, and were converted to MT concentration on the basis
of 7 g atoms of cadmium/MT. An additional aliquot of the lysed
cell suspension was assayed for protein with Bio-Rad Protein
Assay (Bio-Rad Laboratories, Hercules, CA, USA). The total MT
concentrations in the cells were expressed as mgM Tm g
protein
71.
Immunohistochemical staining for MT
Cells were seeded in 4-chamber slides with 5610
4 cells per cham-
ber and allowed to attach for 24 h. Cells were then treated with
10 mM CdCl2 for 24 h and then washed twice with PBS. The
immunohistochemical staining technique for MT was previously
described (Deng et al, 1998). Brieﬂy, cells were ﬁxed in 1% paraf-
ormaldehyde in PBS for 10 min at room temperature. Endogenous
peroxidase activity was inactivated by quenching the cells in 3.0%
hydrogen peroxide for 5 min. Cells were incubated with 10%
normal goat serum for 45 min, followed by incubation with poly-
clonal rabbit anti-MT serum (1:400) for 2 h at room temperature.
This antibody was generated against a polymer of rat liver MT but
readily cross-reacts with human MT. Normal rabbit serum substi-
tuted for the primary antibody was used as negative control.
Subsequently, cells were incubated with biotinylated goat anti-
rabbit IgG and then with avidin-biotin horseradish peroxidase
complex following the manufacturer’s instruction (ABC Kit, Vector
Laboratories, Burlingame, CA, USA). Staining was developed with
0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB) with
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Table 1 Oestrogen-receptor and p53 expression in human epithelial
breast cancer cell lines
Breast cancer cell lines
Oestrogen-receptor
(ER) status p53 status
MCF7 +
c +
a
HCC1806 7
d 7
d
HCC1419 7
d 7
d
HCC1569 7
d 7
d
MDA-MB-231 7
c 7
a
HS578t 7
c 7
a
MDA-MB-468 +
c 7
b
MDA-MB-435 +
c 7
a
+Presence of wild-type oestrogen receptor or p53. 7No wild-type oestrogen
receptor or p53. +Weakly detectable expression of oestrogen-receptor mRNA
using RT–PCR at 30 cycles (Zeillinger et al, 1996).
aO’Connor et al, 1997.
bRunnebaum et al, 1991.
cZeillinger et al, 1996.
dATCC cell lines.
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0.3% ammonia solution, dehydrated and mounted.
RNA isolation and RT–PCR
Cells grown in 75-cm
2 T ﬂasks were treated with 10 mM CdCl2 for
24 h and then washed twice with PBS. Total RNA was isolated
from the cells with TRIzol Reagent (GIBCO BRL, Life Technolo-
gies, Grand Island, NY, USA) according to the manufacturer’s
instructions. RNA was extracted with chloroform followed by
centrifugation to separate the solution into aqueous and organic
phases. RNA was recovered from the aqueous phase by precipita-
tion with isopropyl alcohol and suspended in diethyl
pyrocarbonate-treated water. The concentration of isolated RNA
was measured by spectrophotometry at 260 nm and RNA samples
with purity greater than 1.6 (260/280 nm ratio) were used for
reverse transcription.
First strand cDNA synthesis was performed using Superscipt-II
system (GIBCO BRL, Life Technologies, Gaithersburg, MD,
USA). RNA was added to Oligo (dT) primers (GIBCO BRL), dena-
tured at 708C, and quenched on ice for 10 min. Five micrograms
of RNA were reverse transcribed for 50 min at 428C with super-
script Moloney murine leukaemia virus reverse transcriptase
(GIBCO BRL) and dNTP in a total reaction volume of 20 ml.
The reaction was terminated by a 7 min incubation at 708C.
The resulting reverse transcribed product was then used for PCR
ampliﬁcation performed with the oligonucleotide primers speciﬁc
for human MT-II (GIBCO BRL). MT-II primer sequences were
as follows: 5-CTC TTC AGC ACG CCA TGG AT-3 (sense) and
5-CGC GTT CTT TAC ATC TGG GA-3 (antisense). The predicted
size of the ampliﬁed product (cDNA) was 203 bp for MT-II. PCR
was performed under the following conditions with a thermal
cycler. Each sample contained 1 mM of the sense and antisense
primers for MT-II, 16PCR buffer (GIBCO BRL), 1.0 mM MgCl2
(GIBCO BRL), 250 mM dNTP (GIBCO BRL) and 2.5 U ml
71 Taq
DNA polymerase (GIBCO BRL) in a ﬁnal volume of 50 ml. PCR
was carried out for 23 cycles with denaturation at 948C for 45 s,
annealing at 558C for 30 s, and extension at 728C for 1 min
30 s, with a ﬁnal elongation step at 728C for 10 min. Simulta-
neously, a housekeeping gene, b-actin, was ampliﬁed in a
separate set of tubes using the same RT product and similar cycling
parameters. b-actin primer sequences were as follows: 5'-CCT CTA
TTC CAA CAC AGT GC-3' (sense) and 5'-CAT CGT ACT CCT
GCT TGC TG-3' (antisense), with predicted product size of
210 bp.
Following PCR, a 10 ml aliquot of the RT–PCR cDNA was elec-
trophoresed in 3% agarose gel in Tris/acetic acid/EDTA (TAE)
buffer for 70 min at 100 V, stained with ethidium bromide, and
visualised with UV light. The intensity of the cDNA bands was
analysed by densitometry, and MT-II mRNA expression was
normalised with b-actin.
In situ apoptosis detection
Cells were seeded in 8-chamber slides with 5610
4 cells per cham-
ber and allowed to attach for 24 h. Cells were then treated with
CdCl2 for varying time points and treatment was stopped by wash-
ing twice with PBS. The method of TdT-mediated
deoxyribonucleotide triphosphate-digoxigen nick end labelling
(TUNEL) was used for in situ labelling of apoptotic cells. Staining
was conducted according to the manufacturer’s instruction (Apop-
Tag Peroxidase In Situ Apoptosis Detection Kit, Intergen Co.).
Brieﬂy, cells were ﬁxed in 1% paraformaldehyde in PBS for
10 min at room temperature, followed by post-ﬁx in pre-cooled
ethanol:acetic acid 2:1 for 5 min at 7208C. Endogenous peroxi-
dase was inactivated by quenching the cells in 3.0% hydrogen
peroxide for 5 min. Terminal deoxynucleotidyl transferase (TdT)
enzyme and digoxigenin-labelled dUTP were applied to the
sections for 1 h at 378C. Cells were then washed in stop/wash
buffer and treated with anti-digoxigenin peroxidase conjugate for
30 min at room temperature. Staining was developed with 0.05%
3,3'-diaminobenzidine tetrahydrochloride (DAB) with 0.33%
hydrogen peroxide, counterstained with haematoxylin and 0.3%
ammonia solution, dehydrated and mounted. Apoptotic cells were
examined at 4006 magniﬁcation, counted in 10 randomly selected
ﬁelds, and expressed as a per cent of total cells.
Determination of CdCl2 uptake
Cells grown in 75-cm
2 T ﬂasks were treated with 10 mM of
109CdCl2 and incubated as described earlier for 8 or 24 h, and then
washed twice with PBS. Cells were collected by trypsinisation
followed by centrifugation at 2000 r.p.m. for 2 min. The cell pellet
was resuspended in deionised water and frozen and thawed to lyse
the cells. Disintegrations per minute (d.p.m.) of
109CdCl2 taken up
by the cells were measured by a g counter (1272 Clinigamma, LKB
Wallac) with a counting efﬁciency of 75%. An additional aliquot of
the lysed cell suspension was assayed for protein with Bio-Rad
Protein Assay (Bio-Rad Laboratories) and d.p.m. was expressed
as d.p.m. mg protein
71.
Statistical analysis
Results are expressed as mean+s.e. The statistical evaluation of the
results was performed by one-way ANOVA analysis, followed by
student’s t-test using the error calculated from ANOVA. Signiﬁ-
cance was established at P50.05.
RESULTS
Cell viability after exposure to cadmium
The cell viability of cell lines MCF7 (ER+, p53+), HCC1806 (ER7,
p537) and MDA-MB-231 (ER7, p537) was assessed after expo-
sure to 10–100 mM CdCl2 for 12 h (Figure 1). The viability of
MCF7 cells was unaffected by 10–30 mM CdCl2 treatment for
12 h, but decreased to 96% in response to 40 mM CdCl2. The viabi-
lity of MCF7 cells further decreased as the concentration of CdCl2
was increased, and was 0% with 80 mM CdCl2 exposure. Both
HCC1806 and MDA-MB-231 cells were more resistant to CdCl2
treatment. HCC1806 cells did not show any decrease in cell viabi-
lity in response to 10–100 mM CdCl2. MDA-MB-231 cells showed
a 6% decrease in viability after exposure to 70 mM CdCl2, and at
100 mM CdCl2 the viability was 85%.
Induction of MT by cadmium
When these cells were treated to ZnSO4 (30–60 mM), no signiﬁcant
differences in MT induction were observed in the different cell
lines (data not shown). When cells were treated with oestrogen
(1–100 nM), there was no induction of MT (data not shown).
The induction of MT by cadmium was examined in eight epithelial
breast cancer cell lines differing in p53 and ER status (Table 1).
Cells were treated with 10 mM of CdCl2 for 24 h to induce MT
expression and basal and induced MT levels were measured with
the
109Cd-haeme assay (Figure 2). The cell lines showed a range
of basal MT levels, with MCF7 at 0.55+0.05 mg MT mg protein
71
and the other cell lines at 0.43+0.02 to 2.06+0.11 mgM Tm g
protein
71. Following the induction of MT with 10 mM CdCl2 for
24 h, MCF7 cells showed the highest MT expression at
5.93+0.25 mg MT mg protein
71, while other cell lines showed
lower MT expression ranging from 1.54+0.06 to 3.21+0.19 mg
MT mg protein
71. The ratios of induced MT/basal MT were calcu-
lated, and interestingly, MCF7 cells showed the highest induction
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(9), 1019–1026of MT by 10.79+1.36-fold, while other cell lines showed induction
by 1.40+0.10 to 3.65+0.30-fold. Treatment with 10 mM CdCl2 for
24 h strongly induced MT in MCF7 cells, which are p53+/ER+,
compared to a smaller induction in other cell lines that are
p537/ER7 or p537/ER+.
Localisation of MT after exposure to cadmium
The localisation of MT in MCF7 and HCC1806 cells after treat-
ment with 10 mM CdCl2 for 24 h was determined by
immunohistochemical staining using a polyclonal rabbit antibody
to MT. Prior to CdCl2 treatment, only a light staining for MT
was observed, mainly in the cytoplasm of both cell lines (Figure
3a,b). After exposure to 10 mM CdCl2 for 24 h, intense staining
was observed in the cytoplasm and nucleus of MCF7 cells (Figure
3c). In contrast, HCC1806 cells showed staining in the cytoplasm
with a weak staining in the nucleus (Figure 3d). Negative control
slides incubated with normal rabbit serum showed no staining
for MT.
Induction of MT mRNA expression by cadmium
To investigate the induction of MT mRNA by cadmium, the cell
lines MCF7, HCC1806 and MDA-MB-231 were treated with
10 mM CdCl2 for 12 h and mRNA levels were compared. Total
RNA was isolated from the cell lines and 5 mg of RNA was
subjected to RT–PCR analysis using a primer speciﬁc for human
MT-II and a primer for b-actin simultaneously. PCR products were
electrophoresed on agarose gel and stained with ethidium bromide.
The intensities of the bands were measured and MT-II mRNA
expression was normalised with b-actin. At 23 cycles of PCR, this
analysis showed a signiﬁcant increase in MT-II mRNA expression
in MCF7 cells following CdCl2 treatment, but little change in
HCC1806 and MDA-MB-231 cells was observed (Figure 4). The
induction of MT-II mRNA was calculated and expressed as a ratio
of treated cells/control cells. Results showed a greater induction of
MT-II mRNA expression in MCF7 cells (by 1.61+0.08-fold) than
in HCC1806 cells and MDA-MB-231 cells (by 1.11+0.13 and
1.25+0.06-fold, respectively).
Detection of apoptosis induced by cadmium
The terminal deoxyribonucleotidyl transferase mediated dUTP nick
end labelling method (TUNEL) was used to determine the number
of apoptotic bodies in epithelial breast cancer cells present follow-
ing CdCl2 treatment. Based on the cell viability data, the
concentrations of 10 to 40 mM of CdCl2 were selected to treat
MCF7 and MDA-MB-231 cells for different time points between
4 to 48 h to induce apoptosis. Apoptotic cells were identiﬁed by
the appearance of speciﬁc nuclear staining, condensed nucleus
and/or formation of apoptotic bodies as examined at 4006 magni-
ﬁcation (Figure 5). The number of apoptotic cells was expressed as
a per cent of total cells counted. At 10, 20, 30 and 40 mM of CdCl2,
the highest number of apoptotic bodies in MCF7 cells was
observed between 6–8 h and again at 48 h (Figure 6a, data shown
only for 40 mM CdCl2 treatment). In MDA-MB-231 cells, apoptosis
remained at a constant low level at all the time points examined
between 4 to 48 h (Figure 6a, data shown only for 40 mM CdCl2
treatment). In MCF7 cells at all time points tested, the number
of apoptotic cells increased as the concentration of CdCl2 was
increased, while in MDA-MB-231 cells, there was again a constant
low level of apoptosis (Figure 6b, data shown only for 8 h time
period).
Uptake of cadmium by different cell lines
The uptake of Cd by MCF7, MDA-MB-231, and MDA-MB-435
cells was determined by treating the cells with
109CdCl2 and then
measuring radioactivity. The results are expressed as d.p.m. mg
protein
71. The results show no signiﬁcant differences in cadmium
uptake in these cell lines at 8 or 24 h of treatment (Figure 7). The
data suggest a similar Cd uptake and uniform accumulation of Cd
in these cell lines.
DISCUSSION
This study demonstrates a potential role of p53 on the expression
and induction of MT in human epithelial breast cancer cells. Our
results show that epithelial breast cancer cells with differential p53
expression exhibit differences in induction of MT, and response to
toxicity following treatment with cadmium. Although cadmium
caused induction of MT in all cell lines regardless of ER and p53
status, MCF7 cells showed a much higher induction in MT protein
and mRNA levels as compared to cell lines that are p537 and
ER7/+ (Figure 2). Cell viability results and TUNEL staining for
apoptosis both showed a greater sensitivity of MCF7 cells to toxi-
city induced by cadmium as compared to MDA-MB-231 (p537,
ER7) and HCC1806 (p537,E R 7) cells (Figures 1 and 6). To
investigate whether these differences are due to differential accu-
mulation of cadmium, the uptake of cadmium in the cell lines
was determined by treating the cells with
109CdCl2 and calculating
the radioactivity as
109Cd d.p.m. mg protein
71. Our studies on
cadmium uptake showed that the different cell lines have similar
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Figure 1 Effects of CdCl2 on cell viability. MCF7, MDA-MB-231, and
HCC1806 cells were treated with various concentrations of CdCl2 for
12 h. Cell viability was determined with Procheck Cell Viability Assay and
expressed as a per cent of control. Results are mean+s.e. of three inde-
pendent experiments. * Signiﬁcantly different from control at P50.05.
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Figure 2 Induction of MT expression with CdCl2. Epithelial breast can-
cer cells were treated with 10 mM CdCl2 for 24 h. MT protein levels were
determined with
109Cadmium-haeme assay and expressed as mgM Tm g
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71. Results are mean+s.e. of three independent experiments.
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induction and greater sensitivity to cadmium-induced toxicity in
MCF7 cells is not a consequence of greater accumulation of
cadmium, but may be a consequence of positive p53 expression.
The presence of p53 in MCF7 cells likely mediates the dose- and
time-dependent apoptosis observed during treatment with CdCl2.
In contrast, the absence of p53 in MDA-MB-231 cells appears to
render the cells resistant to apoptosis when treated with CdCl2
(10–40 mM) from 4 to 48 h.
The presence of wild-type p53 and occurrence of apoptosis may
be important indicators of MT expression, since the expression and
induction of MT has been associated with protection against oxida-
tive stress and apoptosis. Cadmium is a potent inducer of MT
synthesis that not only acts through metal response elements of
the MT gene to up-regulate gene transcription (Karin et al,
1984), but can also cause intracellular free radical generation and
lipid peroxidation, DNA damage and a characteristic apoptotic
response (El Azzouzi et al, 1994; Yang et al, 1997). Apoptosis
induced by cadmium is preceded by the participation of oxidative
stress, with up-regulation of oxidant stress genes such as
glutathione S-transferase and g-glutamylcysteine synthetase, activa-
tion of redox sensitive transcription factor AP-1 and NF-kB, as
well as induction of MT-1 and MT-II synthesis (Hart et al, 1999;
Zhou et al, 1999). Several mechanisms may be involved in the
protective effect of MT against metal toxicity and apoptosis. MT
has been shown to bind cadmium and to sequester it away from
important cellular organelles (Goering and Klaassen, 1984). In
addition, MT may have antioxidant properties because of its high
cysteine content which may protect against DNA damage (Cai et
al, 1996). A recent study has shown that treatment of MCF7 cells
with 10 mM CdCl2 can increase MT-IIA isoform and can protect
against cadmium toxicity (Me ￿plan et al, 1999). Since MCF7 cells
were much more sensitive to cadmium toxicity as compared to
HCC1806 and MDA-MB-231, a higher induction of MT in
MCF7 cells may be required to protect against cytotoxicity and
DNA damage.
The tumour suppressor protein p53 plays a role in regulation of
cell cycle progression, DNA repair and apoptosis. The p53 activity
is sensitive to oxidative stress and exposure to heavy metals. These
conditions and DNA strand breaks can induce p53 and initiate
apoptosis in cells. In order to understand the role of MT in apop-
tosis and the effect of p53, we have used epithelial cells with p53+/
ER+ along with epithelial cells with p537/ER7, and the results
suggest that only MCF7 cells with p53+ can induce MT and induce
apoptosis. The p53 activity may inﬂuence the expression of MT by
several potential mechanisms. The p53 protein, which is a tran-
scription factor, can activate or repress the expression of genes in
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Figure 3 Immunohistochemical staining for MT with rabbit polyclonal anti-MT serum which cross-reacts with human MT. Control cells: MCF7 (A), and
HCC1806 (B). Cells treated with 10 mM CdCl2 for 24 h: MCF7 (C), and HCC1806 (D). Positive staining is brown in colour. Magniﬁcation 4006.
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Figure 4 MT-II expression at 23 PCR cycles. RT–PCR was used to ana-
lyse total RNA samples derived from three epithelial breast cancer cell
lines: HCC1806, MDA-MB-213, and MCF7. PCR products were electro-
phoresed on agarose gel and stained with ethidium bromide. Control cells
are represented by C and cells treated with 10 mM CdCl2 for 24 h are re-
presented by Cd. Intensities of cDNA bands were analysed by densitome-
try and MT-II mRNA expression was normalised with b-actin. Changes in
MT-II mRNA expression following treatment were calculated as a ratio
of treated cells/control cells and indicated in the graph. Results are
mean+s.e. of three independent experiments. *Signiﬁcantly different from
control cells at P50.05.
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demonstrated that zinc binding is crucial for p53 protein stabilisa-
tion and DNA binding (Hainaut and Milner, 1993). Since MT may
be involved in zinc homeostasis, it can regulate the supply of zinc
to p53 protein for its optimum activity and also protect the cells
from toxicity to metals and free radicals. Lastly, zinc is known to
inhibit the activation of both caspase 3 (Perry et al, 1997) and
Ca/Mg-dependent endonuclease (Cohen and Duke, 1984), which
play critical roles in the execution of apoptosis. MT, as a zinc bind-
ing protein, may also act as an anti-apoptotic factor. Thus, the
expression of MT and p53 may play a critical role to determine
whether cells undergo apoptosis or proceed to cell cycle stages.
The localisation of MT has important implications on its func-
tions. Positive staining for MT has been demonstrated in various
human tumours and can be localised in the cytoplasm and nucleus,
often depending on cellular differentiation and proliferation (Cher-
ian and Apostolova, 2000). Both MCF7 and HCC1806 cells showed
mainly cytoplasmic staining for MT prior to induction with
cadmium (Figure 3a,b). Nuclear staining noted in a few cells were
associated with proliferative activity as noted by morphology in the
immunohistochemical staining. However, following treatment with
10 mM CdCl2, intense staining for MT was observed in the nucleus
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Figure 5 In situ detection of apoptotic bodies using TUNEL technique. Control cells: MCF7 (A), and MDA-MB-231 (B). Cells treated with 40 mM CdCl2
for 8 h: MCF7 (C), and MDA-MB-231 (D). Cells treated with 40 mM CdCl2 for 24 h: MCF7 (E), and MDA-MB-231 (F). TUNEL-positive apoptotic bodies
are stained brown. Magniﬁcation 4006.
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Figure 6 In situ detection of cadmium-induced apoptosis using the TU-
NEL technique. (A) MCF7 and MDA-MB-231 cells were treated with
40 mM CdCl2 for different time periods. (B) MCF7 and MDA-MB-231 cells
were treated with various concentrations of CdCl2 for 8 h. Apoptotic
bodies were counted in randomly selected ﬁelds. Results are mean+s.e.
of 10 randomly selected ﬁelds. *Signiﬁcantly different from control at
P50.05.
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Figure 7 Uptake of CdCl2 by different cell lines. MCF7, MDA-MB-231
and MDA-MB-435 cells were treated with 10 mM of
109CdCl2 and disinte-
grations per minute (d.p.m.) were measured and expressed as d.p.m. mg
protein
71 at (A) 8 h, and (B) 24 h after treatment. Results are mean+s.e.
of three independent experiments.
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British Journal of Cancer (2002) 87(9), 1019–1026 ã 2002 Cancer Research UKand cytoplasm of MCF7 cells, but not in HCC1806 cells (Figure
3c,d). The nuclear localisation of MT in MCF7 cells was associated
with strong sensitivity towards cadmium-induced toxicity and the
presence of p53. As mentioned, MT may participate in regulating
p53 stability and DNA-binding activity, and in protecting cells
against cadmium-induced toxicity, p53-induced reactive oxygen
intermediates, and apoptotic DNA damage. These activities require
MT to be present in the nucleus. This is in accordance with the
suggested functions of nuclear MT: donation of zinc to transcrip-
tion factors for DNA synthesis, regulation of gene expression,
protection of the nucleus from oxidative damage, and protection
of the DNA from damage and apoptosis (Cherian and Apostolova,
2000).
Activities of p53 are intricately linked to MT induction and
localisation. p53 causes cell cycle arrest at G1 in response to low
levels of stress (Schwartz and Rotter, 1998), and studies have
shown localisation of MT in the nucleus occurs during G1/S phase
when the requirement for zinc is highest (Cherian and Apostolova,
2000). p53 initiates apoptosis during high levels of stress (Schwartz
and Rotter, 1998), and MT has been shown to play a role in differ-
ent aspects of apoptosis. Further evidence is provided by a recent
study showing that cadmium can affect the stability and DNA-
binding activity of p53 (Me ￿plan et al, 1999). In MCF7 cells,
10 mM of CdCl2 caused an increase in p53 protein level and
DNA binding activity. However, at higher concentrations (20 mM
or greater), cadmium down-regulated p53 protein levels and
DNA-binding. Interestingly, in the present study, MCF7 cells
showed a strong induction of MT only when treated with 10 mM
CdCl2 and not higher concentrations (20–50 mM, data not shown).
This demonstrates a correlation between strong MT induction and
p53 activity.
Evidence points to a relationship between p53 and MT expres-
sion and induction in epithelial breast cancer cells. Higher basal
MT expression is associated with p53 mutations in breast cancer
cells (Friedline et al, 1998; Jin et al, 2000). Both factors indicate
and may contribute to progression and poor prognosis of the
cancer. In contrast, activation of p53 by cadmium is accompa-
nied by high induction of MT. Besides protecting cells against
cadmium-induced oxidative stress and DNA damage, MT may
have an essential role in regulating p53 stabilisation and gene
transcription, as well as protecting cells against p53-mediated
apoptosis. Although the presence of ER may affect basal MT
expression, the induction of MT seems to be unaffected by ER
since cell lines weakly positive for ER did not show a signiﬁ-
cantly higher induction of MT compared to the cell lines
negative for ER. Nonetheless, further studies are needed to ascer-
tain the roles of p53 and ER in MT expression and induction.
Additionally, more extensive work with different cell types may
help to determine the tissue-speciﬁcity of any effect of p53 on
MT induction.
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